AstraZeneca Recalls Sample Bottles Containing Eight Brilinta 90mg Tablets

AstraZeneca announced that it is voluntarily recalling one lot of physician sample bottles containing eight tablets of Brilinta (ticagrelor) 90mg tablets as a precautionary measure. The voluntary recall follows a report that a sample bottle containing eight tablets of Brilinta 90mg also contained another medicine called Zurampic (lesinurad) 200 mg tablets which is also manufactured by AstraZeneca. Unintentional dosing with Zurampic has the potential to lead to adverse renal effects including acute renal failure which is more common when Zurampic is given alone as it should be used in combination with a xanthine oxidase inhibitor. Health care professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the U.S. Food and Drug Association's (FDA) MedWatch Safety Information and Adverse Event Reporting Program. To date, AstraZeneca has not received any reports of adverse events related to this recall. Read the full announcement from the FDA here.

Keywords: Acute Kidney Injury, Xanthine Oxidase

< Back to Listings